ZYME Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Zymeworks Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.48 |
52 Week High | US$13.14 |
52 Week Low | US$6.02 |
Beta | 1.15 |
1 Month Change | -7.83% |
3 Month Change | -29.22% |
1 Year Change | -5.15% |
3 Year Change | -75.41% |
5 Year Change | -58.99% |
Change since IPO | -34.77% |
Recent News & Updates
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Recent updates
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 27We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth
Nov 17Zymeworks: Drop Due To Low Differentiation Against Competition
Jul 05Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals
Dec 11Zymeworks' zanidatamab nabs Breakthrough Therapy tag for biliary tract cancer
Nov 30Shareholder Returns
ZYME | US Biotechs | US Market | |
---|---|---|---|
7D | -2.8% | -0.4% | -0.6% |
1Y | -5.1% | 5.4% | 22.5% |
Return vs Industry: ZYME underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: ZYME underperformed the US Market which returned 22.5% over the past year.
Price Volatility
ZYME volatility | |
---|---|
ZYME Average Weekly Movement | 5.5% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ZYME's share price has been volatile over the past 3 months.
Volatility Over Time: ZYME's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 275 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. Fundamentals Summary
ZYME fundamental statistics | |
---|---|
Market cap | US$604.42m |
Earnings (TTM) | -US$125.97m |
Revenue (TTM) | US$50.46m |
12.0x
P/S Ratio-4.8x
P/E RatioIs ZYME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZYME income statement (TTM) | |
---|---|
Revenue | US$50.46m |
Cost of Revenue | US$130.32m |
Gross Profit | -US$79.85m |
Other Expenses | US$46.12m |
Earnings | -US$125.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.77 |
Gross Margin | -158.24% |
Net Profit Margin | -249.63% |
Debt/Equity Ratio | 0% |
How did ZYME perform over the long term?
See historical performance and comparison